REVANCE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.69 USD | +8.53% |
|
+1.37% | -58.02% |
| 04-26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
| 04-12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Chart calendar Revance Therapeutics, Inc.
fe3f7.xAqq44oAws65vJpqIfhskIyHWB3uJrRs_FnzY0420Sg.nWTDtL1ljoTf-MoGFqcEw8PEOV6MdcU5iC20DhFp4k2PR5yhzm6AlNHVog~46df82286e34c8a05f9d6f4eeb771ff1
Upcoming events on Revance Therapeutics, Inc.
Past events on Revance Therapeutics, Inc.
| 12/04/2024 | American Academy of Neurology Meeting - Aaron Ellenbogen, Robert A. Hauser |
| 12/04/2024 | American Academy of Neurology Meeting - Han Lee, André F. Batista, Conor J. Gallagher |
| 12/03/2024 13:30 | Barclays Global Healthcare Conference |
| 05/03/2024 17:50 | TD Cowen Health Care Conference |
| 28/02/2024 21:30 | Q4 2023 Earnings Call |
| 28/02/2024 21:05 | Q4 2023 Earnings Release |
| 08/02/2024 14:30 | Guggenheim Healthcare Talks Biotechnology Conference |
| 28/11/2023 20:00 | Piper Sandler Healthcare Conference |
| 14/11/2023 16:30 | Stifel Healthcare Conference |
| 08/11/2023 21:30 | Q3 2023 Earnings Call |
| 08/11/2023 21:06 | Q3 2023 Earnings Release |
| 19/09/2023 14:30 | Investor Day |
| 08/08/2023 21:30 | Q2 2023 Earnings Call |
| 08/08/2023 21:05 | Q2 2023 Earnings Release |
| 12/06/2023 16:40 | Goldman Sachs Global Healthcare Conference - Fireside Chat |
| 06/06/2023 22:00 | William Blair Growth Stock Conference - Fireside Chat |
| 09/05/2023 21:30 | Q1 2023 Earnings Call |
| 09/05/2023 21:05 | Q1 2023 Earnings Release |
| 03/05/2023 16:00 | Annual General Meeting |
| 18/04/2023 17:45 | Needham Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,41 2,68 -84.57% | 15,3 13,2 15.91% | 77,8 75,8 2.66% | 133 129 2.92% | 234 226 3.38% | 282 |
|
EBITDA Million USD | Released Forecast Spread | -162 -158 -2.4% | -263 -239 -10.05% | -255 -218 -16.68% | -308 -184 -67.78% | -160 -151 -5.66% | -97,8 |
|
EBIT Million USD | Released Forecast Spread | -164 -161 -2.15% | -273 -262 -4.2% | -275 -268 -2.46% | -342 -261 -30.83% | -317 -331 4.27% | -178 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -159 -159 -0.55% | -285 -284 -0.42% | -281 -290 3.05% | -356 -297 -19.73% | -324 -334 2.98% | -185 |
|
Net income Million USD | Released Forecast Spread | -159 -157 -1.3% | -282 -284 0.51% | -281 -288 2.32% | -356 -296 -20.36% | -324 -334 3% | -185 |
|
EPS USD | Released Forecast Spread | -3,67 -3,58 -2.42% | -4,86 -4,88 0.41% | -4,17 -4,26 2.15% | -4,90 -4,07 -20.33% | -3,83 -3,98 3.73% | -2,07 |
| Announcement Date | 24/02/20 | 22/02/21 | 28/02/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 26,0 24,7 4.92% | 25,3 23,9 5.81% | 28,4 27,8 2.16% | 29,0 28,2 2.75% | 49,9 45,1 10.69% | 49,3 46,2 6.75% | 58,1 58,9 -1.36% | 56,8 58,7 -3.35% | 69,8 62,1 12.4% | 56,7 | 68,2 | 69,7 | 85,3 | 79,4 |
|
EBITDA Million USD | Released Forecast Spread | -56,2 -45,5 -23.46% | -56,8 -45,5 -25.04% | -52,4 -45,2 -15.82% | -72,0 -49,9 -44.42% | -127 -41,2 -208.2% | |||||||||
|
EBIT Million USD | Released Forecast Spread | -61,6 -63,5 3.05% | -62,2 -60,5 -2.87% | -57,8 -56,6 -2.11% | -77,5 -65,5 -18.29% | -144 -77,0 -87.49% | -58,0 -66,1 12.26% | -65,5 -61,2 -7.09% | -139 -79,6 -75.05% | -54,0 -68,3 21.04% | -68,8 | -42,2 | -40,4 | -27,4 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -63,1 -71,1 11.2% | -64,3 -66,3 2.92% | -61,4 -63,2 2.73% | -84,0 -68,8 -22.03% | -146 -91,0 -60.46% | -59,8 -69,1 13.46% | -67,3 -63,9 -5.34% | -141 -81,7 -72.5% | -55,7 -69,4 19.79% | -70,3 | -44,1 | -42,5 | -29,6 | |
|
Net income Million USD | Released Forecast Spread | -63,1 -68,8 8.29% | -64,3 -66,4 3.03% | -61,4 -63,2 2.73% | -84,7 -68,8 -23.05% | -146 -91,0 -60.46% | -59,8 -69,1 13.46% | -67,3 -63,9 -5.34% | -141 -81,9 -72.34% | -55,7 -69,4 19.79% | -70,3 | -44,1 | -42,5 | -29,6 | |
|
EPS USD | Released Forecast Spread | -0,93 -1,02 8.82% | -0,94 -0,96 2.08% | -0,88 -0,91 3.56% | -1,17 -0,94 -25% | -1,90 -1,04 -82.69% | -0,74 -0,84 12.32% | -0,80 -0,79 -1.78% | -1,63 -0,94 -73.87% | -0,62 -0,81 23.08% | -0,72 | -0,51 | -0,48 | -0,37 | -0,49 |
| Announcement Date | 28/02/22 | 10/05/22 | 09/08/22 | 08/11/22 | 28/02/23 | 09/05/23 | 08/08/23 | 08/11/23 | 28/02/24 | - | - | - | - | - |
More events
Past sector events for Revance Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RVNC Stock
- Calendar Revance Therapeutics, Inc.
